Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LLY
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
LLY
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

LLY Price Prediction Next Week

Based on the comprehensive data analysis and recent market developments, here's the price prediction for LLY for the next trading week:

Technical Analysis

  • Current price: $784.09 (as of Jan 24 close)
  • Key Fibonacci levels show strong resistance at $794.83 and support at $733.45
  • RSI(14) at 53.47 indicates neutral momentum
  • MACD at -7.83 suggests slight bearish pressure in short term
  • 20-day SMA at $771.26 acts as immediate support
  • 200-day SMA at $838.33 indicates long-term uptrend

News Impact Analysis

  • FDA approval for monthly maintenance dosing of Leqembi, competing with LLY's Kisunla, could create some competitive pressure
  • Trump administration's potential healthcare policies appear favorable for pharmaceutical companies, with focus on PBM reform rather than direct drug pricing
  • Q4 2024 earnings release scheduled for February 4, with analysts expecting EPS of $5.43, up 118.1% YoY

Price Prediction for Next Week Based on technical and fundamental factors:

  • Bullish Target: $795 (Fibonacci R1)
  • Bearish Target: $733 (Fibonacci S1)
  • Most Likely Range: $760-$785

Trading Recommendation: HOLD

  • Current price level shows consolidation near support
  • While long-term outlook remains positive due to strong drug pipeline and favorable policy environment, short-term technical indicators suggest caution
  • Wait for earnings release before making new positions
  • Key entry point for buyers would be around $760 level with stop loss at $733

Based on the comprehensive data analysis and recent market developments, here's the price prediction for LLY for the next trading week:

Technical Analysis

  • Current price: $784.09 (as of Jan 24 close)
  • Key Fibonacci levels show strong resistance at $794.83 and support at $733.45
  • RSI(14) at 53.47 indicates neutral momentum
  • MACD at -7.83 suggests slight bearish pressure in short term
  • 20-day SMA at $771.26 acts as immediate support
  • 200-day SMA at $838.33 indicates long-term uptrend

News Impact Analysis

  • FDA approval for monthly maintenance dosing of Leqembi, competing with LLY's Kisunla, could create some competitive pressure
  • Trump administration's potential healthcare policies appear favorable for pharmaceutical companies, with focus on PBM reform rather than direct drug pricing
  • Q4 2024 earnings release scheduled for February 4, with analysts expecting EPS of $5.43, up 118.1% YoY

Price Prediction for Next Week Based on technical and fundamental factors:

  • Bullish Target: $795 (Fibonacci R1)
  • Bearish Target: $733 (Fibonacci S1)
  • Most Likely Range: $760-$785

Trading Recommendation: HOLD

  • Current price level shows consolidation near support
  • While long-term outlook remains positive due to strong drug pipeline and favorable policy environment, short-term technical indicators suggest caution
  • Wait for earnings release before making new positions
  • Key entry point for buyers would be around $760 level with stop loss at $733

LLY Similar Chart Price Prediction

The price of LLY is predicted to go up 12.72%, based on the high correlation periods with LMND. The similarity of these two price pattern on the periods is 92.06%.

stocks logo

LLY

stocks logo

LMND

Up: 12.72%Similarity: 92.06%

LLY Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

LLY Price Forecast($)

Potential Return(%)

2025

787.140

0.660

2026

1,050.000

29.460

2027

1,200.000

47.950

2028

1,200.000

47.950

2029

1,200.000

47.950

2030

1,200.000

47.950

What is LLY stock price prediction 2025 ?

LLY stock is currently trading at $787.14. Based on its strong growth drivers, including high demand for Mounjaro and Zepbound, and expected revenue growth from new drug launches, the stock could reach $850-$900 by the end of 2025. However, risks such as regulatory challenges and competition in the weight-loss drug market may limit upside potential.

What is LLY stock price prediction 2026 ?

LLY stock is projected to reach $1,050 by 2026, driven by strong demand for its GLP-1 drugs like Mounjaro and Zepbound, alongside a robust pipeline in diabetes and Alzheimer's treatments. The company's innovative portfolio and expanding manufacturing capacity position it for sustained growth. However, execution risks and competition in the weight-loss market could temper upside potential.

What is LLY stock price prediction 2027 ?

LLY stock is projected to reach approximately $1,200 by 2027, driven by strong growth in its GLP-1 drugs like Mounjaro and Zepbound, which dominate the obesity and diabetes markets. The company’s robust pipeline, expanding manufacturing capacity, and increasing demand for innovative treatments support this forecast. However, execution risks and competition from peers like Novo Nordisk could influence the trajectory.

What is LLY stock price prediction 2028 ?

LLY stock is projected to reach approximately $1,200 by 2028, driven by strong growth in its diabetes and obesity drugs, Mounjaro and Zepbound, alongside its Alzheimer's treatment, Kisunla. The company’s robust pipeline, expanding production capacity, and increasing demand for GLP-1 drugs position it for sustained revenue growth. However, execution risks and competition in the weight-loss drug market could moderate gains.

What is LLY stock price prediction 2029 ?

LLY stock is projected to reach approximately $1,200 by 2029, driven by strong growth in its GLP-1 drugs like Mounjaro and Zepbound, alongside advancements in Alzheimer's and oncology treatments. The company's robust pipeline, expanding revenue base, and leadership in innovative therapies support this long-term valuation. However, execution risks and market competition could influence the trajectory.

What is LLY stock price prediction 2030 ?

Eli Lilly's (LLY) stock price is projected to reach approximately $1,200 by 2030, driven by strong growth in its diabetes and obesity treatments, particularly Mounjaro and Zepbound, alongside a robust pipeline in Alzheimer's and oncology drugs. The company's consistent innovation, expanding manufacturing capacity, and increasing global demand for GLP-1 drugs position it for sustained revenue growth. However, potential risks include competition from low-cost alternatives and regulatory challenges.

LLY Revenue Forecast

LLY EPS Forecast

LLY FAQs

What is bull’s view on LLY?

LLY stock is currently trading at $804. Analysts maintain a bullish view, with price targets ranging from $970 to $1,190, driven by strong growth in GLP-1 drugs like Mounjaro and Zepbound, which dominate the weight loss market. Despite recent volatility, the stock is supported by robust fundamentals and a promising pipeline, making it a long-term growth candidate.

What is bear's view on LLY?

LLY stock currently trades at $804, showing resilience despite recent volatility. Bearish sentiment arises from its high valuation (Forward P/E of 31.82) and slowing growth in key drugs like Mounjaro and Zepbound, which missed sales expectations in late 2024. Additionally, technical analysis indicates $722 as a critical support level, and a breach could signal further downside.

What is LLY revenue forecast for next quarter？

The market consensus for LLY's revenue in the upcoming quarter is projected to be approximately $12.977B USD.

What is LLY eps forecast for next quarter？

The market consensus for LLY's eps in the upcoming quarter is projected to be approximately $4.918 USD.

LLY VS S&P500

Lilly's strong leadership in weight-loss drugs should drive industry-leading growth with approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.

Lilly's cancer drug Verzenio reported strong data in early-stage breast cancer, opening up the strong potential in this multi-billion-dollar market.

Lilly is developing a new Alzheimer's drug (donanemab) that could become a major blockbuster, especially because the FDA appears to have a lower threshold for approval for this disease.

Ask Intellectia about LLY

LLY Analyst's Forecast

Tim Anderson

B of A Securities

Strong Buy

Price Target

$997

Upside

+24.69%

BofA analyst Tim Anderson reinstated coverage of Eli Lilly with a Buy rating and $997 price target. Eli Lilly is "likely to see bouts of volatility" on obesity-related news flow, but should be a core long-term holding due to its outsized, durable long-term growth and many "protective moats," the analyst tells investors.
Carter Gould

Barclays

Buy

Price Target

$1,025 → $975

Upside

+17.47%

Geoff Meacham

B of A Securities

Strong Buy

Price Target

$1,150 → $1,100

Upside

+32.53%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free